ArticleEmergency medicine Australasia : EMA2026
The Safety of Single Aminoglycoside Dose in Emergency Departments (SAD-ED) Among Patients With and Without Chronic Kidney Disease: A Retrospective Cohort Study.
Article in Emergency medicine Australasia : EMA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveNephrotoxicity has been reported with prolonged use of aminoglycosides but is considered low-risk with single-dose empirical therapy. However, limited data exist in patients with chronic kidney disease (CKD). The aim of this study was to determine the safety of single-dose aminoglycosides (SDA) in Emergency Departments (ED) in patients with and without CKD.
methodsA retrospective cohort study was performed in four tertiary hospitals within a multi-site Australian metropolitan hospital network. Electronic medical records of all adult patients who presented to ED and received SDA between August 2019-July 2024 were screened for inclusion. The primary outcome was AKI incidence within 1 week of SDA.
resultsOverall, 6636 aminoglycoside administrations were identified, 1835 screened and 660 patients were included. Patients received gentamicin (74.1%), tobramycin (25.6%), or amikacin (0.3%). Patients with CKD were older (81.3 vs. 64.1 years, p < 0.001) and had more comorbidities. AKI incidence within 1 week of hospitalisation was higher in patients with vs. without CKD (30.9% vs. 13.4%, p < 0.001). Patients with CKD had more severe AKI (stage 2: 10.1% vs. 2.6%, p < 0.001) and had numerically, but not statistically, higher mortality and intensive care unit admission rates compared to patients without CKD. CKD was associated with a higher likelihood of AKI incidence (OR 2.88 [95% CI: 1.76-4.71], p < 0.001).
conclusionsPatients with CKD who received single-dose aminoglycosides were more likely to have AKI compared to patients without CKD. Clinicians should carefully balance the risks and benefits of empiric aminoglycosides in patients with CKD and consider such therapy only if no other suitable alternatives exist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.